|
1
|
Noto H, Goto A, Tsujimoto T and Noda M:
Cancer risk in diabetic patients treated with metformin: A
systematic review and meta-analysis. PLoS One. 7:e334112012.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Witters LA: The blooming of the French
lilac. J Clin Invest. 108:1105–1107. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bodmer M, Meier C, Krähenbühl S, Jick SS
and Meier CR: Long-term metformin use is associated with decreased
risk of breast cancer. Diabetes Care. 33:1304–1308. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chuang JC and Jones PA: Epigenetics and
microRNAs. Pediatr Res. 61:24R–29R. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Latronico MV, Catalucci D and Condorelli
G: MicroRNA and cardiac pathologies. Physiol Genomics. 34:239–242.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Liu J, Valencia-Sanchez MA, Hannon GJ and
Parker R: MicroRNA-dependent localization of targeted mRNAs to
mammalian P-bodies. Nat Cell Biol. 7:719–723. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Filipowicz W, Bhattacharyya SN and
Sonenberg N: Mechanisms of post-transcriptional regulation by
microRNAs: Are the answers in sight? Nat Rev Genet. 9:102–114.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Esquela-Kerscher A and Slack FJ: Oncomirs
- microRNAs with a role in cancer. Nat Rev Cancer. 6:259–269. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liu T, Tang H, Lang Y, Liu M and Li X:
MicroRNA-27a functions as an oncogene in gastric adenocarcinoma by
targeting prohibitin. Cancer Lett. 273:233–242. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mertens-Talcott SU, Chintharlapalli S, Li
X and Safe S: The oncogenic microRNA-27a targets genes that
regulate specificity protein transcription factors and the
G2-M checkpoint in MDA-MB-231 breast cancer cells.
Cancer Res. 67:11001–11011. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang X, Tang S, Le SY, Lu R, Rader JS,
Meyers C and Zheng ZM: Aberrant expression of oncogenic and
tumor-suppressive microRNAs in cervical cancer is required for
cancer cell growth. PLoS One. 3:e25572008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lerner M, Lundgren J, Akhoondi S, Jahn A,
Ng HF, Moqadam F Akbari, Vrielink JA Oude, Agami R, Den Boer ML,
Grandér D, et al: MiRNA-27a controls FBW7/hCDC4-dependent cyclin E
degradation and cell cycle progression. Cell Cycle. 10:2172–2183.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mertens-Talcott SU, Noratto GD, Li X,
Angel-Morales G, Bertoldi MC and Safe S: Betulinic acid decreases
ER-negative breast cancer cell growth in vitro and in vivo: role of
Sp transcription factors and microRNA-27a:ZBTB10. Mol Carcinog.
52:591–602. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Banerjee N, Talcott S, Safe S and
Mertens-Talcott SU: Cytotoxicity of pomegranate polyphenolics in
breast cancer cells in vitro and vivo: Potential role of miRNA-27a
and miRNA-155 in cell survival and inflammation. Breast Cancer Res
Treat. 136:21–34. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hardie DG: AMP-activated protein kinase:
An energy sensor that regulates all aspects of cell function. Genes
Dev. 25:1895–1908. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hardie DG, Carling D and Gamblin SJ:
AMP-activated protein kinase: Also regulated by ADP? Trends Biochem
Sci. 36:470–477. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jørgensen SB, Viollet B, Andreelli F,
Frøsig C, Birk JB, Schjerling P, Vaulont S, Richter EA and
Wojtaszewski JF: Knockout of the α2 but not
α1 5-AMP-activated protein kinase isoform abolishes
5-aminoimidazole-4-carboxamide-1-β-4-ribofuranosidebut not
contraction-induced glucose uptake in skeletal muscle. J Biol Chem.
279:1070–1079. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Musi N, Hirshman MF, Nygren J, Svanfeldt
M, Bavenholm P, Rooyackers O, Zhou G, Williamson JM, Ljunqvist O,
Efendic S, et al: Metformin increases AMP-activated protein kinase
activity in skeletal muscle of subjects with type 2 diabetes.
Diabetes. 51:2074–2081. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fox MM, Phoenix KN, Kopsiaftis SG and
Claffey KP: AMP-activated protein kinase α 2 isoform suppression in
primary breast cancer alters AMPK growth control and apoptotic
signaling. Genes Cancer. 4:3–14. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kim YH, Liang H, Liu X, Lee JS, Cho JY,
Cheong JH, Kim H, Li M, Downey TJ, Dyer MD, et al: AMPKα modulation
in cancer progression: Multilayer integrative analysis of the whole
transcriptome in Asian gastric cancer. Cancer Res. 72:2512–2521.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu J, Liu W, Ying H, Zhao W and Zhang H:
Analysis of microRNA expression profile induced by AICAR in mouse
hepatocytes. Gene. 512:364–372. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Evans JM, Donnelly LA, Emslie-Smith AM,
Alessi DR and Morris AD: Metformin and reduced risk of cancer in
diabetic patients. BMJ. 330:1304–1305. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bowker SL, Majumdar SR, Veugelers P and
Johnson JA: Increased cancer-related mortality for patients with
type 2 diabetes who use sulfonylureas or insulin: Response to
Farooki and Schneider. Diabetes Care. 29:1990–1991. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhou G, Myers R, Li Y, Chen Y, Shen X,
Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, et al: Role of
AMP-activated protein kinase in mechanism of metformin action. J
Clin Invest. 108:1167–1174. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shaw RJ, Lamia KA, Vasquez D, Koo SH,
Bardeesy N, Depinho RA, Montminy M and Cantley LC: The kinase LKB1
mediates glucose homeostasis in liver and therapeutic effects of
metformin. Science. 310:1642–1646. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hemminki A, Avizienyte E, Roth S, Loukola
A, Aaltonen LA, Järvinen H and de la Chapelle A: A serine/threonine
kinase gene defective in Peutz-Jeghers syndrome. Duodecim.
114:667–668. 1998.(In Finnish). PubMed/NCBI
|
|
27
|
Markman B, Atzori F, Pérez-García J,
Tabernero J and Baselga J: Status of PI3K inhibition and biomarker
development in cancer therapeutics. Ann Oncol. 21:683–691. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bell DS: Successful utilization of
aliskiren, a direct renin inhibitor in Bartter syndrome. South Med
J. 102:413–415. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zakikhani M, Dowling R, Fantus IG,
Sonenberg N and Pollak M: Metformin is an AMP kinase-dependent
growth inhibitor for breast cancer cells. Cancer Res.
66:10269–10273. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ben Sahra I, Laurent K, Loubat A,
Giorgetti-Peraldi S, Colosetti P, Auberger P, Tanti JF, Le
Marchand-Brustel Y and Bost F: The antidiabetic drug metformin
exerts an antitumoral effect in vitro and in vivo through a
decrease of cyclin D1 level. Oncogene. 27:3576–3586. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hirsch HA, Iliopoulos D, Tsichlis PN and
Struhl K: Metformin selectively targets cancer stem cells, and acts
together with chemotherapy to block tumor growth and prolong
remission. Cancer Res. 69:7507–7511. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cufí S, Vazquez-Martin A,
Oliveras-Ferraros C, Martin-Castillo B, Joven J and Menendez JA:
Metformin against TGFβ-induced epithelial-to-mesenchymal transition
(EMT): From cancer stem cells to aging-associated fibrosis. Cell
Cycle. 9:4461–4468. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lee YS and Dutta A: MicroRNAs in cancer.
Annu Rev Pathol. 4:199–227. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kim KB, Lotan R, Yue P, Sporn MB, Suh N,
Gribble GW, Honda T, Wu GS, Hong WK and Sun SY: Identification of a
novel synthetic triterpenoid,
methyl-2-cyano-3,12-dioxooleana-1,9-dien-28-oate, that potently
induces caspase-mediated apoptosis in human lung cancer cells. Mol
Cancer Ther. 1:177–184. 2002.PubMed/NCBI
|
|
35
|
Ma Y, Yu S, Zhao W, Lu Z and Chen J:
miR-27a regulates the growth, colony formation and migration of
pancreatic cancer cells by targeting Sprouty2. Cancer Lett.
298:150–158. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hassan MQ, Gordon JA, Beloti MM, Croce CM,
van Wijnen AJ, Stein JL, Stein GS and Lian JB: A network connecting
Runx2, SATB2, and the miR-23a~27a~24-2 cluster regulates the
osteoblast differentiation program. Proc Natl Acad Sci USA.
107:19879–19884. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Dobreva G, Chahrour M, Dautzenberg M,
Chirivella L, Kanzler B, Fariñas I, Karsenty G and Grosschedl R:
SATB2 is a multifunctional determinant of craniofacial patterning
and osteoblast differentiation. Cell. 125:971–986. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lee CW, Wong LL, Tse EY, Liu HF, Leong VY,
Lee JM, Hardie DG, Ng IO and Ching YP: AMPK promotes p53
acetylation via phosphorylation and inactivation of SIRT1 in liver
cancer cells. Cancer Res. 72:4394–4404. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Cooper AC, Fleming IN, Phyu SM and Smith
TA: Changes in [18F]Fluoro-2-deoxy-D-glucose incorporation induced
by doxorubicin and anti-HER antibodies by breast cancer cells
modulated by co-treatment with metformin and its effects on
intracellular signalling. J Cancer Res Clin Oncol. 141:1523–1532.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kim SJ, Oh JS, Shin JY, Lee KD, Sung KW,
Nam SJ and Chun KH: Development of microRNA-145 for therapeutic
application in breast cancer. J Control Release. 155:427–434. 2011.
View Article : Google Scholar : PubMed/NCBI
|
